Bringing the fundamentals into focus…
Back to AgomAb Therapeutics NV
How AgomAb Therapeutics NV stacks up
AGMB · against 385 other Healthcare companies of similar size
Valuation
0/ 100
Near the bottom of its peers.
Ranked #351 of 386 · scores higher than 0% of peers
Bars: peers in each 10-point band of the valuation score150 peers with a valuation score of 0–9, including AGMB · Click a bar to see the companies
Why valuation scores 0?
Weighted metrics compared with all Healthcare companies.Mainly because of its earnings yield and EBITDA yield, which are weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -10.4% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. EBITDA yield: -138.3% vs peer median 4.0%
- Free cash flow yield is not reported, so it is left out of the score.
Metric by metric
Position: dot = AGMB, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | AGMB | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 369 reported | Not reported | -0.4% | — | — | 30% |
| EBITDA yieldHigher is better · 389 reported | -138.3% | 1.9% | 4% | 50% | |
| Free cash flow yieldHigher is better · 191 reported | Not reported | -9.4% | — | — | 20% |
| Book yieldHigher is better · 378 reported | 43.9% | 50.5% | 44% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by valuation score
Top 5 and the companies ranked around AGMBScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score